Clinical trials: Advanced Intestinal Cancer
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Metastatic Colon Cancer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202-01) in patients with previously treated RAS mutant advanced or metastatic CRC.
- Trial name
- NCT05983367
- Testing
- Ompenaclid, Bevacizumab, FOLFIRI regimen
- Where
- 28 sites in Belgium, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Inspirna, Inc.
Metastatic Colorectal Cancer
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.
- Trial name
- XCITE (NCT01767857)
- Testing
- Xilonix
- Where
- 113 sites in United States, Australia and 11 more
- Volunteers
- 643 people
- Sponsor
- Janssen Research & Development, LLC
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Advanced Adenocarcinoma
Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
This study was a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColoSense test, which is a multi-target stool RNA test for colorectal cancer screening.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Serrated Polyp
- Trial name
- CRC-PREVENT (NCT04739722)
- Testing
- ColoSense
- Where
- 2 sites in United States
- Volunteers
- 14,263 people, healthy volunteers welcome
- Sponsor
- Geneoscopy, Inc.
Colorectal Cancer, Colorectal Cancer Metastatic
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
This phase I/II studies the side effects and best dose of regorafenib when given together with pembrolizumab in treating participants with colorectal cancer that has spread to other places in the body.
- Trial name
- NCT03657641
- Testing
- Pembrolizumab, Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of Southern California
Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
This phase I trial studies the side effects and best dose of ropidoxuridine and how well it works when added to the usual chemotherapy treatment (capecitabine) during radiation therapy for the treatment of patients with stage…
- Conditions
- Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04406857
- Testing
- Capecitabine, Radiation Therapy, Ropidoxuridine
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
This phase I trial studies the best dose and side effects of talimogene laherparepvec in combination with 5-fluorouracil, leucovorin, oxaliplatin, capecitabine, and chemoradiation before surgery in treating patients with rectal…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7
- Trial name
- NCT03300544
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
- Trial name
- NCT02375672
- Testing
- Pembrolizumab, mFOLFOX6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hoosier Cancer Research Network
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Neoplasm, Head and Neck Neoplasm
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker.
- Conditions
- Colorectal Neoplasm, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm
- Trial name
- NCT00423150
- Testing
- Temozolomide
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
Rectal Cancer
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the…
- Trial name
- NCT02933944
- Testing
- TG02-treatment, Pembrolizumab
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 6 people
- Sponsor
- Targovax ASA
Colorectal Cancer
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of…
- Trial name
- NCT01057017
- Testing
- intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brown University
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03095781
- Testing
- XL888, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University